within Pharmacolibrary.Drugs.ATC.A;

model A05AA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A05AA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ursodoxicoltaurine (also known as tauroursodeoxycholic acid, TUDCA) is a bile acid derivative that has cytoprotective, anti-apoptotic, and anti-inflammatory properties. It is used investigationally for various liver and metabolic diseases, and neurodegenerative disorders. It is not widely approved as a pharmaceutical drug in most countries, but is available as a supplement and being studied clinically.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic (PK) data specific to ursodoxicoltaurine in humans have been reported in the published literature. Parameter values shown below are estimates based on known properties of bile acids and related drugs. Estimated for typical adult oral administration.</p><h4>References</h4><ol><li><p>Li, N, et al., &amp; Xu, H (2023). Simultaneous determination of UDCA and its major metabolites in human plasma with surrogate matrix by a rapid and specific LC-MS/MS method. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1223 123726–None. DOI:<a href=&quot;https://doi.org/10.1016/j.jchromb.2023.123726&quot;>10.1016/j.jchromb.2023.123726</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37148852/&quot;>https://pubmed.ncbi.nlm.nih.gov/37148852</a></p></li><li><p>Olsen, TW, et al., &amp; Wiedmann, TS (2020). Drug Tissue Distribution of TUDCA From a Biodegradable Suprachoroidal Implant versus Intravitreal or Systemic Delivery in the Pig Model. <i>Translational vision science &amp; technology</i> 9(6) 11–None. DOI:<a href=&quot;https://doi.org/10.1167/tvst.9.6.11&quot;>10.1167/tvst.9.6.11</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32821508/&quot;>https://pubmed.ncbi.nlm.nih.gov/32821508</a></p></li><li><p>Simoni, P, et al., &amp; Roda, A (2013). A new point-of-care portable immunosensor for non-invasive assessment of oro-ileal transit time by oral fluid tauroursodeoxycholate measurement after its oral load. <i>Journal of pharmaceutical and biomedical analysis</i> 81-82 1–7. DOI:<a href=&quot;https://doi.org/10.1016/j.jpba.2013.03.013&quot;>10.1016/j.jpba.2013.03.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23587552/&quot;>https://pubmed.ncbi.nlm.nih.gov/23587552</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A05AA05;
